Vinblastine
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-VINBLASTINE |
|---|---|
| Type | Drug |
| Aliases | VelbanВінбластин |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Vinca alkaloid (microtubule inhibitor) |
|---|---|
| Mechanism | Binds tubulin → blocks microtubule polymerization + mitotic spindle → metaphase arrest + apoptosis. Less neurotoxic than vincristine, more myelotoxic. |
| Typical dosing | ABVD: 6 mg/m² IV days 1+15 of 28-day cycle |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- FATAL if intrathecal — never inject into CNS
Notes
Used in ABVD (Hodgkin), other regimens. Cap at 12 mg total dose typical. Hepatic dose adjustment for total bilirubin >3 mg/dL.
Used By
Regimens
REG-A-AVD- A+AVD (Brentuximab vedotin + Adriamycin + Vinblastine + Dacarbazine), 6 cyclesREG-ABVD- ABVD (Adriamycin + Bleomycin + Vinblastine + Dacarbazine), 2-6 cyclesREG-AV-HEPATIC-MODIFIED- AV (Doxorubicin + Vinblastine, ABVD-modified for HL with severe hepatic impairment Child-...REG-NIVO-AVD- N+AVD (Nivolumab + Adriamycin + Vinblastine + Dacarbazine), 6 cycles — emerging 1L standa...